Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Sermorelin

GHRH (1-29), GRF 1-29 NH2, Sermorelin acetate

Quick Stats
Studies 223
Trials 41
Completed NA INTERVENTIONAL NCT00324064

Sexually Dimorphic Effects of GHRH in Adult Growth Hormone Testing

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

Specific Aim 1 Healthy male and female subjects and growth hormone (GH) deficient subjects display sexually dimorphic GH responses to GHRH administration Specific Aim 2 GH responses to GHRH in both healthy controls and in GH deficient patients correlate with expression and activity of the stimulatory G proteins, G alpha q and G alpha S. G protein levels correlate with gonadal steroid levels. Specific Aim 3 Sexually dimorphic GH responses to GHRH are enhanced in Tanner Stage V compared to Tanner Stage 1 individuals

Detailed Description

Growth hormone deficiency affects disproportionately more males than females. Although ascertainment bias plays a role in this sexual dimorphism, no plausible mechanism to fully explain this difference has been proposed. This investigator initiated study will provide currently unavailable data on sexual/age differences in response to GH stimulation testing. Data obtained from the study may provide a basis for developing appropriate normal ranges for adult GH testing, may provide a plausible mechanism for the enhanced hormone responsiveness observed in females, and may provide data on when the sexual differences to GH stimulation may develop. The objectives of this study are to: 1. Confirm the sexual dimorphism in growth hormone responses for adult growth hormone testing in healthy male and female subjects 2. Correlate peak Growth Hormone Releasing Hormone (GHRH)/arginine induced growth hormone responses with G protein levels in healthy subjects and in patients with a history of childhood GH deficiency 3. Determine whether sexual dimorphism is acquired during puberty

Interventions

Name: GHRH/arginine stimulation testing
Type: PROCEDURE
Description: GHRH(Geref) 1mcg/kg IVP followed by Arginine 10% solution 0.5mg/kg (maximum of 30 Gm) infused over 30 minutes. Labs drawn 6 times over 2 hours.

Primary Outcomes

Measure: Serum GH levels in response to GHRH/arginine stimulation
TimeFrame: End of study
Description:

Trial Information

NCT ID

NCT00324064

Status

Completed

Study Type

INTERVENTIONAL

Phases

NA

Sponsor

Children's Mercy Hospital Kansas City

Last Updated

December 15, 2025

Related Peptides